FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Top Story

Sanofi-Aventis readies $18.7B bid for Genzyme

Genzyme (GENZ) is in play. After days of fevered speculation over what Genzyme would be worth to a company like Sanofi-Aventis, the big pharma outfit appears to have set its sights on the low side of the spectrum. According to a flurry of news reports, Sanofi CEO Chris Viehbacher and the board think that $70 a share--that's $18.7 billion total--would be a fair price to pay. But any bidding could start under that level. Read more...

More News

Five high-value biotech stocks

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value plays in the months ahead. In the mood for some market risk analysis? Then check out these five companies. Report

Special Report

Top 5 Biotech VC Deals of 2010

The first half of 2010 has drawn to a close, so it's time to look back on the biggest biotech venture capital deals so far this year. Overall, the biotech industry has raised $2.1 billion in 238 deals through the end of June 2010, according to the National Venture Capital Association. See the list